Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

for heart failure and need for repeat vascularization. Strikingly, this analysis found a significant association between injected cell volume and improvement in ejection fraction that is suggestive of a dose effect. This summation of prior studies supports Amorcyte's subsequent prospective findings.

"Having successfully confirmed a dose effect, Amorcyte looks forward to proceeding with a larger prospective randomized trial and furthering our clinical program with AMR-001," said Andrew Pecora, M.D., Chairman of the Board of Amorcyte. "These strong Phase I results, combined with proprietary innovative technologies that address the challenges of commercializing stem cell products, position us to bring to market a stem cell therapy with the potential to address a serious unmet patient need."

About Cardiovascular Disease

It is estimated that each year there are approximately 1.1 million instances of acute myocardial infarction (AMI). 160,000 AMIs are severe enough to cause ventricular remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling.

About Amorcyte, Inc.

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and ot
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/8dzk58/blood_screening ... "Blood Screening Market by Technology (Nucleic Acid Amplification ... Sequencing, Western Blotting), Product (Instrument, Reagent) & End ... " report to their offering. ... $2.55 billion by 2019 from $1.5 billion in ...
(Date:4/1/2015)... 2014 /CNW/ - Canada,s Research-Based Pharmaceutical ... newly released report on Cost Drivers of Public Drug Plans ... to the report, the rates of change in drug costs ... of -0.8 percent in 2012/13 for a number of select ... examines the costs of medicines without considering their overall impact ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/8glw2m/forensic ) ... Technologies and Services - Global Strategic Business Report" ... report analyzes the US market for Forensic Technologies ... Segments: Forensic Databases, Forensic Consulting and Computer Forensics, ... estimates and forecasts are provided for the period ...
(Date:4/1/2015)... , April 1, 2015 Synthetic Biologics, ... therapies for serious infections and diseases, with a ... clinical data supporting the development of SYN-004, the ... intravenous (IV) antibiotics within the gastrointestinal (GI) tract ... microbiome for the prevention of C. difficile ...
Breaking Biology Technology:Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 3Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 5Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 6Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 7Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4
... Expanded Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... Inc., a life,sciences company developing revolutionary bench-top flow cytometer ... C financing led by,Fidelity Biosciences and Flagship Ventures. Current ...
... Mich., July 8 GeneGo, Inc., the leading,systems ... Center,at Yale has become a certified GeneGo Center ... GeneGo,s MetaCore, training and advanced,support., The W. ... of the largest biotechnology laboratories of its kind ...
... TechCFO, a leading provider of outsourced CFO-level financial and management services ... Strickland as Partner to its Boston office. Strickland is the latest ... of last year. , ... Cambridge, MA (PRWEB) July ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Yale Keck Microarray Center Becomes a GeneGo Center of Excellence 2TechCFO Adds Gary Strickland as Partner in Boston Office 2
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... for some time that exercise induces neurogenesis in a ... the underlying mechanism was not fully understood. The hippocampus ... and is one of the brain regions where new ... precursor cell maturation , The researchers demonstrated that ...
... described as "orphan diseases, too small to be noticed, ... Lorenzo,s Oil, rare diseases are getting unprecedented attention today ... and marketing new medicines that promise fuller lives for ... That,s the finding of a major examination, published today ...
... at protecting leaves from being chomped by slugs, suggests research ... Although they lurk in the soil, they seem to protect ... amount of damage slugs do to individual plants. Spanish ... worst alien species in Europe and are considered a pest ...
Cached Biology News:Serotonin mediates exercise-induced generation of new neurons 2Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 2Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 3Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 4Renaissance in new drugs for rare diseases: Report in world's largest scientific socity magazine 5
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
... PS10 ProteinChip Arrays are preactivated with carbonyl ... primary amine groups. The PS10 array contains ... PS1 array, but with an updated hydrophobic ... chips with 2 mm diameter spots spatially ...
...
Biology Products: